Nasdaq
$2.09▼ 0.48%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $37.9MShares out 18.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
38- 2d agoPre-market26.10.23 19:036-KKey event#●●●#●●●
ALTERITY THERAPEUTICS LTD
Alterity Therapeutics has announced a proposed issue of securities. This filing was submitted as part of the company's capital raising and securities issuance process.…more
$2.09-0.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoPre-market26.10.23 19:026-KKey event
ALTERITY THERAPEUTICS LTD
Alterity Therapeutics has submitted a notification regarding unquoted securities. This filing formalizes changes related to the company's unquoted securities within its capital structure.…more
$2.09-0.48%vs prev closeView filingShare - 2d agoPre-market26.10.23 19:006-KKey event
ALTERITY THERAPEUTICS LTD
Alterity Therapeutics has filed a notification regarding unquoted securities with the SEC. This filing formalizes changes to the company's securities related to its capital structure.…more
$2.09-0.48%vs prev closeView filingShare
37 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9Pre-market26.10.09 20:05#●●●#●●●
Alterity Therapeutics to Present at Canaccord Genuity Conference
Alterity Therapeutics announced that its CEO will present at the upcoming Canaccord Genuity Drug and Device Conference. This event involves corporate presentations and investor discussions, which is a standard investor relations activity.…more
$2.09-0.48%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Pre-market26.10.05 20:05
●●●●●●●● ●●●●● ●●●●●●
Alterity Therapeutics reported that its MSA treatment candidate ATH434 slowed functional decline by approximately 52% compared to placebo in a Phase 2 trial analysis. These findings will support the design and implementation of the company's upcoming Phase 3 clinical trial.…more
$2.09-0.48%vs prev close - 9.3Pre-market26.09.03 20:05
●●●●●●●● ●●●●● ●●●●●●
Alterity Therapeutics announced that its CEO will participate in a fireside chat at the Cantor Global Healthcare Conference on September 11, 2026. The session will provide an opportunity to discuss the company's clinical progress and strategic outlook.…more
$2.09-0.48%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report